Center for Immunotherapy and Cell-Based Technologies
Novosibirsk — Kaliningrad — Moscow — Irkutsk
Main →
Colorectal cancer
Xenovaccinotherapy for cancer
http://www.medicalnewstoday.com/rss/cancer-oncology.xmlhttp://www.medicalnewstoday.com/rss/immune_system.xmlhttp://www.medicalnewstoday.com/rss/multiple_sclerosis.xmlhttp://www.medicalnewstoday.com/rss/stem_cell_research.xml
24.01.2012
According to a study published January 23 online in Cancer, many smokers do not drop the habit after being diagnosed with colorectal or lung cancer. ...
15.12.2011
A research team in France has bred a lab mouse with a gene mutation that allows colorectal cancer tumors to grow because the protein coded by the ge...
07.12.2011
An increasing understanding of molecular pathways that regulate breast and colorectal cancer development and progression has produced new therapeutic ...
15.11.2011
A study published Online First in The Lancet Oncology shows that CT colonography as an additional primary colorectal cancer-screening test could resul...
28.10.2011
According to an announcement made by Bayer HealthCare Pharmaceuticals, the Phase III trial of its investigational compound regorafenib (BAY 73-4506) t...
18.10.2011
According to two new investigations published online in Genome Research , independent investigation teams have for the first time discovered a specifi...
30.09.2011
Each year, around 5,000 people die from colorectal cancer in Austria, with the mortality rate being just under 50 per cent. A screening colonoscopy (b...
29.09.2011
Even if health care is free, colorectal cancer screening rates among those without financial means are still low, and results of a new study suggest t...
22.09.2011
According to a study published in a recent issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Re...
19.08.2011
A study published online on yesterday in the Journal of the National Cancer Institute shows, that lower levels of colorectal cancer (CRC) incidence an...
Immunotherapy for cancer
An active specific immunotherapy (vaccinotherapy) is a strategy using tumor-associated antigens for including antitumor immune responses. The small structural distinctions of the xenogenic tumor-associated antigens from their human analogues render these antigens highly immunogenic and capable of including immune-mediated, antitumor responses in a patient not only at early, but also at advanced stages of disease, when tumor-derived immunosuppression is significant. Tumor-specfic immunotherapy is able to generate a selective and long-term antitumor effect. Such a therapy has no complications attributable to chemotherapy.
Xenovaccinotherapy for cancer